Efficacy of omega-3 polyunsaturated fatty acids on hormones, oxidative stress, and inflammatory parameters among polycystic ovary syndrome: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is a close relationship between hormones, oxidative stress, and inflammatory factors and polycystic ovary syndrome (PCOS). This meta-analysis was conducted to evaluate the changes in hormones, oxidative stress, and inflammatory factors of PCOS patients who were supplemented with omega-3 polyunsaturated fatty acids (n-3 PUFAs). METHODS: The databases of PubMed, Cochrane Library, Embase, and Web of Science were searched from inception to February 2021. We have included all randomized controlled trials (RCTs) that reported the n-3 PUFA treatment in PCOS. Weighted mean differences (WMD) and 95% confidence interval (CI) were calculated, and either the fixed effects model or random effects model was used. RESULTS: 314 studies were initially identified, and 10 RCTs with 610 patients were finally included in the current study. Results suggested that PCOS patients with n-3 PUFAs supplementation may have a reduction in C-reactive protein (CRP; -8.97 mg/dL; 95% CI: -17.66 to -0.28 mg/dL; P=0.04; I2=99%); serum malondialdehyde (MDA; -0.40 mg/dL; 95% CI: -0.56 to -0.25 mg/dL; P<0.00001; I2=42); luteinizing hormone (LH; -1.33 mg/dL; 95% CI: -2.63 to -0.04 mg/dL; P=0.04; I2=0%); serum total testosterone (TT; -0.11 mg/dL; 95% CI: -0.18 to -0.04 mg/dL; P=0.02; I2=73%); and an increase in total antioxidant capacity (TAC; 72.24 mg/dL; 95% CI: 22.32 to 122.16 mg/dL; P=0.005; I2=50%) and serum sex hormone binding globulin (SHBG; 0.68 mg/dL; 95% CI: 0.06 to 1.31 mg/dL; P=0.03; I2=0%).However, no effect on glutathione (GSH; -12.63 mg/dL; 95% CI: -50.34 to 25.07 mg/dL; P=0.51; I2=56%), dehydroepiandrosterone sulfate (DHEAS; -0.01 mg/dL; 95% CI: -1.53 to 1.50 mg/dL; P=0.99; I2=78%), free androgen index (FAI; 0.00 mg/dL; 95% CI: -0.03 to 0.03 mg/dL; P=0.99; I2=0%), or follicle-stimulating hormone (FSH; 0.37 mg/dL; 95% CI: -0.55 to 1.29 mg/dL; P=0.43; I2=61) was found. CONCLUSIONS: This meta-analysis showed that supplementation of n-3 PUFAs in PCOS women can significantly improve CRP, MDA, LH, TT, TAC, and SHBG, but did not affect the concentrations of GSH, DHEAS, FAI, or FSH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The same meta-analysis mentioned above in Section 4.3.2 reported that n-3 PUFA reduces serum hs-CRP and malondialdehyde while improving serum total antioxidant capacity [86].”
From Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome (2024) · cites this paper as [86]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis of ten randomized controlled trials including 610 patients found that n-3 PUFA decreases serum total testosterone and increases SHBG in women with PCOS [86].”
From Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome (2024) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Amini, M., Bahmani, F., Foroozanfard, F., Vahedpoor, Z., Ghaderi, A., Taghizadeh, M., Karbassizadeh, H., & Asemi, Z. (2024) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2018.1508282 · Cited by 31 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundRetractedDuval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099 · cited 1×
“A funnel plot was used to judge publication bias (20).”
MethodShamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120 · cited 1×
“Methods Protocol and registration The systematic review and meta-analyses were conducted in accordance with the PRISMA guidelines (17).”
MethodTeede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 2×
“Ann Palliat Med 2021;10(8):8991-9001 | https://dx.”
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488 · cited 2×
“It is the most common endocrine disorder, is accompanied by a multitude of conditions, and affects 6–20% of reproductive-age women (1,2).”
BackgroundDeUgarte, C. M., Bartolucci, A. A., & Azziz, R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.070 · Cited by 589 · cited 1×
“Hyperandrogenism and its related consequences are notable clinical features of PCOS, and is present in up to 50–75% of women with PCOS (3).”
BackgroundLong-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis
Wekker, V, van Dammen, L., Koning, A., Heida, K. Y., Painter, R. C., Limpens, J., Laven, J. S. E., Roeters van Lennep, J. E., Roseboom, T. J., & Hoek, A. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa029 · Cited by 425 · cited 1×
“It is the most common endocrine disorder, is accompanied by a multitude of conditions, and affects 6–20% of reproductive-age women (1,2).”
BackgroundOsibogun, O., Ogunmoroti, O., & Michos, E. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.010 · Cited by 423 · cited 1×
“In recent years, studies have shown that dietary fat is currently considered as a biological regulator affecting metabolism, and ω- Polyunsaturated fatty acids (n-3PUFA) may be the most effective metabolic fatty acid regulator (12-15).”
BackgroundPolycystic ovarian syndrome (PCOS): Long-term metabolic consequences
Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018) · Metabolism · doi:10.1016/j.metabol.2017.09.016 · Cited by 416 · cited 1×
“Hyperandrogenism also increases the risk of cardiovascular and cerebrovascular diseases, type 2 diabetes, endometrial cancer, and other diseases (4,5).”
BackgroundJørgensen, L., Paludan-Müller, A. S., Laursen, D. R. T., Savović, J., Boutron, I., Sterne, J. A. C., Higgins, J. P. T., & Hróbjartsson, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0259-8 · Cited by 396 · cited 1×
“0) (18), each trial was evaluated in the following 7 areas related to the risk of bias: (I) random sequence generation, (II) concealment of treatment allocation, (III) blinding of participants and personnel, (IV) blinding of outcome evaluation, (V) incomplete outcome data, (VI) selective reporting, and (VII) other bia…”
BackgroundKabir, M., Skurnik, G., Naour, N., Pechtner, V., Meugnier, E., Rome, S., Quignard-Boulangé, A., Vidal, H., Slama, G., Clément, K., et al. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1670 · Cited by 316 · cited 1×
“Animal studies shown that n-3 PUFAs can prevent IR by activating PPARa, reducing inflammation, and depositing fat in insulin-sensitive tissues (16).”
BackgroundBarrea, L., Marzullo, P., Muscogiuri, G., Di Somma, C., Scacchi, M., Orio, F., Aimaretti, G., Colao, A., & Savastano, S. (2018) · Nutrition Research Reviews · doi:10.1017/s0954422418000136 · Cited by 171 · cited 1×
“According to those studies, low-grade inflammation cooperates with IR and hyperandrogenism to constitute an interactive continuum acting on the pathophysiology of PCOS (10,11).”
BackgroundSantos, H. O., Price, J. C., & Bueno, A. A. (2020) · Nutrients · doi:10.3390/nu12103159 · Cited by 154 · cited 1×
“In recent years, studies have shown that dietary fat is currently considered as a biological regulator affecting metabolism, and ω- Polyunsaturated fatty acids (n-3PUFA) may be the most effective metabolic fatty acid regulator (12-15).”
BackgroundArtimani, T., Karimi, J., Mehdizadeh, M., Yavangi, M., Khanlarzadeh, E., Ghorbani, M., Asadi, S., & Kheiripour, N. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1371691 · Cited by 138 · cited 1×
“Meanwhile, studies have shown that hyperandrogenemia, inflammation, and oxidative damage play a key role in the pathophysiology of PCOS (6,7).”
BackgroundPolycystic ovary syndrome and mental disorders: a systematic review and exploratory meta-analysis
Blay, S. L., Aguiar, J., & Passos, I. C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91700 · Cited by 111 · cited 1×
“The hormonal imbalance in PCOS patients can influence their reproductive, metabolic, and psychological health, contributing to irregular menstrual cycles, infertility and complications in pregnancy, insulin resistance (IR) in muscle and adipose tissue, hyperinsulinemia, anxiety, and depression (8,9).”
BackgroundPhelan, N., O’Connor, A., Kyaw Tun, T., Correia, N., Boran, G., Roche, H. M., & Gibney, J. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.005538 · Cited by 89
Jamilian, M., Samimi, M., Mirhosseini, N., Afshar Ebrahimi, F., Aghadavod, E., Talaee, R., Jafarnejad, S., Hashemi Dizaji, S., & Asemi, Z. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.027 · Cited by 89 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundVargas, M. L., Almario, R. U., Buchan, W., Kim, K., & Karakas, S. E. (2011) · Metabolism · doi:10.1016/j.metabol.2011.04.007 · Cited by 86 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundRahmani, E., Samimi, M., Ebrahimi, F. A., Foroozanfard, F., Ahmadi, S., Rahimi, M., Jamilian, M., Aghadavod, E., Bahmani, F., Taghizadeh, M., et al. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.09.008 · Cited by 86 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundEfficacy of omega-3 in the treatment of polycystic ovary syndrome
Oner, G., & Muderris, I. I. (2013) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2012.751365 · Cited by 68 · cited 1×
“In recent years, studies have shown that dietary fat is currently considered as a biological regulator affecting metabolism, and ω- Polyunsaturated fatty acids (n-3PUFA) may be the most effective metabolic fatty acid regulator (12-15).”
BackgroundEbrahimi, F. A., Samimi, M., Foroozanfard, F., Jamilian, M., Akbari, H., Rahmani, E., Ahmadi, S., Taghizadeh, M., Memarzadeh, M. R., & Asemi, Z. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-117773 · Cited by 64
Mirmasoumi, G., Fazilati, M., Foroozanfard, F., Vahedpoor, Z., Mahmoodi, S., Taghizadeh, M., Esfeh, N. K., Mohseni, M., Karbassizadeh, H., & Asemi, Z. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-119751 · Cited by 64 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundKarakas, S. E., Perroud, B., Kind, T., Palazoglu, M., & Fiehn, O. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.04.003 · Cited by 50 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundNadjarzadeh, A., Firouzabadi, R. D., Vaziri, N., Daneshbodi, H., Lotfi, M. H., & Mozaffari–Khosravi, H. (2013) · Europe PMC (PubMed Central) · Cited by 46
LORENZ, L. B., & WILD, R. A. (2007) · Clinical Obstetrics and Gynecology · doi:10.1097/grf.0b013e31802f5197 · Cited by 43 · cited 1×
“Effect of n-3 PUFA supplementation on hormones PCOS has clinical heterogeneity, which is based on the influence of genetic and environmental factors (31).”
BackgroundWhy does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?
Ruan, X., Li, M., & Mueck, A. O. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190130104922 · Cited by 43 · cited 1×
“Hyperandrogenism also increases the risk of cardiovascular and cerebrovascular diseases, type 2 diabetes, endometrial cancer, and other diseases (4,5).”
BackgroundHager, M., Nouri, K., Imhof, M., Egarter, C., & Ott, J. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05194-w · Cited by 35 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
BackgroundZuo, T., Zhu, M., Xu, W., Wang, Z., & Song, H. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484074 · Cited by 28 · cited 1×
“Effects of n-3 PUFA supplementation on inflammation and oxidative stress Chronic inflammatory response and inflammatory mediators play a key part in the occurrence and development of IR, which directly affect the phosphorylation and activation of IRS-1 and IRS-2, and cause IR (32).”
BackgroundTalari, H. R., Poladchang, S., Hamidian, Y., Samimi, M., Gilasi, H. R., Ebrahimi, F. A., & Asemi, Z. (2018) · Oman Medical Journal · doi:10.5001/omj.2018.88 · Cited by 26 · cited 1×
“Finally, 10 studies (21-30) were enrolled in our meta-analysis.”
Backgroundde Melo, A. S., Rodrigues, J. K., Jordão, A. A., Ferriani, R. A., & Navarro, P. A. (2016) · Reproduction · doi:10.1530/rep-16-0084 · Cited by 25
Sóter, M. O., Ferreira, C. N., Sales, M. F., Cândido, A. L., dos Reis, F. M., Milagres, K. S., Ronda, C. R. S. C., Silva, I. D. F. O., Sousa, M. O., & Gomes, K. B. (2015) · Cytokine · doi:10.1016/j.cyto.2015.06.008 · Cited by 23
Research works printed but not linked: 2
- Wan X, Wang W, Liu J, et al. Estimating the sample mean © Annals of Palliative Medicine. All rights reserved. Ann Palliat Med 2021;10(8):8991-9001 | https://dx.doi.org/10.21037/apm-21-2018 and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135. · doi:10.21037/apm-21-2018andstandarddeviationfromthesample
- Gray B, Steyn F, Davies PS, et al. Omega-3 fatty acids: a review of the effects on adiponectin and leptin and potential implications for obesity management. Eur J Clin Nutr 2013;67:1234-42. (English Language Editor: J. Jones)
Cited by
Awonuga, A. O., Camp, O. G., & Abu‐Soud, H. M. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01159-6 · Cited by 93
“…on hormones, oxidative stress, and inflammatory parameters among polycystic ovary syndrome: a systematic review and meta-analysis Yuan J et al., [179] Influence of n-3 fatty acid supplementation on inflammatory and oxidative stress markers in patients with polycystic ovary syndrome: a…”
BackgroundZeng, G., You, D., Ye, L., Wu, Y., Shi, H., Lin, J., Jiang, Z., & Wei, J. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1075877 · Cited by 41
“Numerous systematic reviews and meta-analysis have noted that n-3 PUFAs exhibited anti-inflammatory effects on multiple non-communicable diseases, including systemic inflammatory response syndrome (3), colorectal cancer (4), type 2 diabetic mellitus (5), bipolar disorder (6), mental disorders (7), polycystic ovary syn…”
BackgroundScarfò, G., Daniele, S., Fusi, J., Gesi, M., Martini, C., Franzoni, F., Cela, V., & Artini, P. G. (2022) · Biomedicines · doi:10.3390/biomedicines10061305 · Cited by 45
Serum fatty acid profiles associated with metabolic risk in women with polycystic ovary syndrome
Tian, Y., Zhang, J., Li, M., Jie, S., Bai, X., Zhang, H., Wang, Y., Chen, H., & Song, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1077590 · Cited by 25
Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome
Albardan, L., Platat, C., & Kalupahana, N. S. (2024) · Nutrients · doi:10.3390/nu16172961 · Cited by 18
“The same meta-analysis mentioned above in Section 4.3.2 reported that n -3 PUFA reduces serum hs-CRP and malondialdehyde while improving serum total antioxidant capacity [86].”
MethodInfluential
Metadata
- Authors
- Yuan, J., Wen, X., & Jia, M.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Jia, Ming
- Venue
- Annals of Palliative Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-08
- Volume
- 10
- Issue
- 8
- Pages
- 8991-9001
- ISSN
- 2224-5820 (ISSN-L)
- 2224-5839
- OpenAlex
- W3197297734
- Cited by
- 22
- References
- 32
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 2
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Palliative Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- polycystic ovary syndrome, omega-3 polyunsaturated fatty acids, dietary supplementation, oxidative stress, inflammatory markers, C-reactive protein, malondialdehyde, luteinizing hormone, testosterone, sex hormone-binding globulin, total antioxidant capacity, insulin resistance, hyperandrogenism, hyperinsulinemia, lipoatrophy, hirsutism, menstrual irregularity
- MeSH terms
- Female, Hormones, Humans, Polycystic Ovary Syndrome, Sex Hormone-Binding Globulin, Fatty Acids, Omega-3, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.